Exact Sciences Corporation (EXAS)

Market Cap	8.28B
Revenue (ttm)	2.76B
Net Income (ttm)	-1.03B
Shares Out	185.76M
EPS (ttm)	-5.59
PE Ratio	n/a
Forward PE	130.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,681,566
Open	42.85
Previous Close	43.45
Day's Range	42.54 - 45.16
52-Week Range	40.62 - 74.44
Beta	1.14
Analysts	Strong Buy
Price Target	70.59 (+58.42%)
Earnings Date	May 1, 2025

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Ri...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1995
• Employees: 7,000
• Stock Exchange: NASDAQ
• Ticker Symbol: EXAS
• Website: https://www.exactsciences.com

Financial Performance

In 2024, Exact Sciences's revenue was $2.76 billion, an increase of 10.37% compared to the previous year's $2.50 billion. Losses were -$1.03 billion, 404.0% more than in 2023.

Analyst Forecast

According to 18 analysts, the average rating for EXAS stock is "Strong Buy." The 12-month stock price forecast is $70.59, which is an increase of 58.42% from the latest price.

Price Target

$70.59

(58.42% upside)

Analyst Consensus: Strong Buy